Skip to content

Study · Randomized controlled trial · 2022

4 results

Effect of bremelanotide on body weight of obese women: Data from two phase 1 randomized controlled trials.

Spana C, Jordan R, Fischkoff S

Diabetes, obesity & metabolism15 Mar 2022Cited by 13 (Europe PMC)

PMID35170192 (opens in a new tab)PMCIDPMC9314948 (opens in a new tab)DOI10.1111/dom.14672 (opens in a new tab)PepBankPUB-35170192
Read at sourcePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In obese premenopausal women in Study A, bremelanotide produced a significantly greater body weight reduction than placebo after 16 days.

    In plain wordsIn obese women, bremelanotide caused more weight loss than placebo after 16 days.

    Peptide
    Bremelanotide (PT-141)
    Outcome
    DecreaseBody weight change after 16 days (Study A)
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneous · days 1-15As given in this study (human).

    Measurements

    LS mean difference in body weight
    −1.3 kg
    Study A vs placebo

    Source sentences

    Summary
    In Study A, 27 of 30 bremelanotide subjects (90.0%) completed the trial and exhibited a significantly greater reduction in body weight after 16 days versus placebo [least squares mean difference (95% CI), -1.3 (-1.9 to -0.8) kg; p < .0001].
    2 context sentences
    Summary · context
    Study A matched subjects 1:1 to receive subcutaneous placebo or bremelanotide three times daily for days 1-15.
    Summary · context
    Premenopausal women with a body mass index >30 kg/m2 were studied in two phase 1, single-centre, randomized, double-blind, placebo-controlled trials.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In obese premenopausal women in Study A, bremelanotide decreased mean caloric intake versus placebo by about 400 kcal per day.

    In plain wordsIn obese women, bremelanotide lowered daily calorie intake by about 400 kcal compared with placebo.

    Peptide
    Bremelanotide (PT-141)
    Outcome
    DecreaseCaloric intake (Study A)
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneous · days 1-15As given in this study (human).

    Measurements

    Reduction in caloric intake
    ≈ 400 kcal/day
    Study A vs placebo

    Source sentences

    Summary
    Mean caloric intake in bremelanotide subjects was decreased versus placebo, with a magnitude of reduction of approximately 400 kcal/day throughout Study A (p < .01).
    2 context sentences
    Summary · context
    Study A matched subjects 1:1 to receive subcutaneous placebo or bremelanotide three times daily for days 1-15.
    Summary · context
    Premenopausal women with a body mass index >30 kg/m2 were studied in two phase 1, single-centre, randomized, double-blind, placebo-controlled trials.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In obese premenopausal women in the Study B crossover trial, twice-daily bremelanotide produced a significantly greater mean body weight reduction than placebo.

    In plain wordsIn obese women, twice-daily bremelanotide caused more weight loss than placebo over short treatment periods.

    Peptide
    Bremelanotide (PT-141)
    Outcome
    DecreaseBody weight reduction with twice-daily dosing (Study B)
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 4-day treatment periodsAs given in this study (human).

    Measurements

    Mean body weight reduction
    1.7 kg
    twice-daily bremelanotide
    Mean body weight reduction
    0.9 kg
    placebo

    Source sentences

    Summary
    Significantly greater reduction of mean body weight occurred in twice-daily bremelanotide subjects versus placebo (1.7 vs. 0.9 kg, respectively, p < .001).
    2 context sentences
    Summary · context
    Study B was a crossover trial with six distinct treatment sequences consisting of three 4-day treatment periods, investigating once-a-day and twice-a-day exposure to bremelanotide versus placebo.
    Summary · context
    Premenopausal women with a body mass index >30 kg/m2 were studied in two phase 1, single-centre, randomized, double-blind, placebo-controlled trials.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In obese premenopausal women in the Study B crossover trial, total caloric intake fell significantly more with bremelanotide than with placebo.

    In plain wordsIn obese women, bremelanotide lowered total calorie intake more than placebo over short treatment periods.

    Peptide
    Bremelanotide (PT-141)
    Outcome
    DecreaseTotal caloric intake reduction (Study B)
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    Dose not stated · 4-day treatment periodsAs given in this study (human).

    Measurements

    Mean difference in caloric intake
    398 to 469 kcal
    bremelanotide vs placebo

    Source sentences

    Summary
    Total caloric intake reduction was significantly greater in the bremelanotide groups versus placebo (mean difference range: 398-469 kcal; p < .0001).
    2 context sentences
    Summary · context
    Study B was a crossover trial with six distinct treatment sequences consisting of three 4-day treatment periods, investigating once-a-day and twice-a-day exposure to bremelanotide versus placebo.
    Summary · context
    Premenopausal women with a body mass index >30 kg/m2 were studied in two phase 1, single-centre, randomized, double-blind, placebo-controlled trials.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.